# Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

> **NCT00114101** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 460 (actual)

## Conditions studied

- DS Stage I Multiple Myeloma
- DS Stage II Multiple Myeloma
- DS Stage III Multiple Myeloma
- Refractory Multiple Myeloma
- Smoldering Multiple Myeloma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **DRUG:** Melphalan
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Placebo Administration

## Key facts

- **NCT ID:** NCT00114101
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2004-12-15
- **Primary completion:** 2012-12-31
- **Final completion:** 2027-03-06
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00114101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00114101, "Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00114101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*